CHA Bio & Diostech Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CHA Bio & Diostech Co., Ltd.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
- Contract Research, Toxicology Testing-CRO
- Contract Manufacturing Organization
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- CHA Biotech, Co., Ltd.